It is time to change the paradigm for hepatitis C virus testing

Clinical Infectious Diseases

Volumn 54, Issue 9, 2012, Pages 1272-1274

  Deuffic Burban, Sylvie ^a,b   Yazdanpanah, Yazdan ^a,c,d  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MATHEMATICAL MODEL; NOTE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VIRUS TRANSMISSION;

FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MASS SCREENING;

EID: 84859759765     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis047     Document Type: Note

References (29)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14. (Pubitemid 46780630)
2. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50:1750-5.
3. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51:729-33.
4. The Viral Hepatitis Prevention Board (VHPB). Prevention and control of viral hepatitis in Spain: lessons learnt and the way forward. Budapest, Hungary: The Viral Hepatitis Prevention Board meeting, 2010.
5. Varela M, Reig M, de la Mata M, et al. [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc) 2010; 134:569-76.
6. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327-32. (Pubitemid 40770887)
7. Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009; 41:689-99.
8. Mariano A, Caserta C, Pendino GM, et al. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area. Dig Liver Dis 2009; 41:509-15.
9. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
11. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.
12. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
13. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
14. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
15. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54:1137-44.
16. GhanyMG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
17. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141:715-7. (Pubitemid 39434844)
18. EASL International Consensus Conference on Hepatitis C. Paris, France, 26-28 February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30:956-61.
19. Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, 5-6 May 2005. Dig Liver Dis 2006; 38:445-51.
20. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011; 18(Suppl 1):1-16.
21. The Viral Hepatitis Prevention Board (VHPB). Identification and management of persons with chronic viral hepatitis in Europe. Budapest, Hungary: The Viral Hepatitis Prevention Board meeting, 2010.
22. Kew M, Francois G, Lavanchy D, et al. Prevention of hepatitis C virus infection. J Viral Hepat 2004; 11:198-205. (Pubitemid 38658444)
23. Deblonde J, De Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M. Barriers to HIV testing in Europe: a systematic review. Eur J Public Health 2010; 20:422-32.
24. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012; 54:1259-71.
25. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2011; [Epub ahead of print].
26. McGarry LJ, Pawar VS, Parekh HH, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2011; doi:10.1002/hep.25510 [Epub ahead of print].
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed 27 December 2011.
28. Haute Autorité de Santé (HAS). Dépistage de l'infection par le VIH en France: stratégies et dispositif de dépistage. Available at: http://www.has-sante.fr/portail/jcms/c-866949/ depistage-de-linfection-par-le-vih-en-francestrategies-et-dispositif-de- depistage. Accessed 27 December 2011.
29. Garattini L, van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ 2011; 12:499-502.